FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koudinov, A. R.
Right arrow Articles by Koudinova, N. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koudinov, A. R.
Right arrow Articles by Koudinova, N. V.
(The FASEB Journal. 1998;12:1097-1099.)
© 1998 FASEB

Alzheimer's amyloid beta and lipid metabolism: a missing link?

Alexei R. Koudinova,1, Temirbolat T. Berezovb and Natalia V. Koudinovaa

a Weizmann Institute, Department of Neurobiology, Rehovot, 76100 Israel
b Russian Academy of Medical Sciences, Institute of Biomedical Chemistry and Russian Peoples' Friendship University School of Medicine, Department of Biochemistry, Miklucho-Maklay St., 8, Moscow, 117198 Russia

THE EXCELLENT ARTICLE by Baggio et al. was of particular interest to us because it addressed an important issue pertaining to our special subject of Alzheimer's research: the "hypothesis that a continuous reshaping in lipid physiology occurs with age and is a critical factor for survival and successful aging." (1)

The authors are correct that "changes in the serum level of protein, lipids, and lipoproteins that are considered risk factors for atherosclerotic vascular diseases in young people may lose their biological significance and assume a different, unknown role with advanced age." But we are beginning to learn that blood lipids are indeed associated with Alzheimer's disease (AD)2 and our group and others are discovering that Alzheimer's may be very closely linked to human lipid metabolism change.

First, it has been shown (2) that the lecithin cholesterol acyl transferase (LCAT) activity is significantly decreased in Alzheimer's patients. LCAT catalyzes an acyltransferase reaction that forms most of the cholesterol esters and is a key step in reverse cholesterol transport in humans. This makes the enzyme of obvious significance in the development of atherosclerosis and heart disease. Moreover, as was demonstrated a decade ago (3), this is also the case with Down's syndrome (DS), where there are the same blood changes in LCAT activity. This indicates that changes in this enzyme are related to the etiologies of both AD and DS on the one hand and vascular pathology on the other. In addition, there is a remarkable resistance to systemic atherosclerosis in DS (4), which is not yet shown in AD.

Second, it has been proposed (5) that membrane destabilization in Alzheimer's disease as a natural consequence of primary defective lipid composition (5) is important in the membrane damage that leads to brain cell death. The membrane destabilization was found to occur selectively at the areas of neurodegeneration in AD brain, thus potentially accounting for the localized lipid pathology.

Our own research activities are focused on understanding in more detail the normal biology of Alzheimer's amyloid beta protein (Aß). This small protein has a high tendency to form insoluble amyloid aggregates. Amyloid deposition of cerebrovascular amyloid and senile plaques is a characteristic feature of the Alzheimer's brain and the latter was reported to occur in the brain of heart disease patients (6, 7). Nevertheless, in 1992 it became clear that Aß is not just a pathological protein. At that time several research groups (8–10) detected it in a ‘normal’, soluble (sAß), nonaggregated state in blood and cerebrospinal fluid (CSF) of both normal people and patients with AD. The question why this protein does not aggregate normally became of special interest to many Alzheimer's research teams. Published data regarding Aß binding to a number of proteins, and in particular to apolipoproteins in a test tube (11, 12), led us to a hypothesis that these interactions reflect an sAß association with lipoproteins, of which apolipoproteins are protein constituents.

Evidence described in our recently published papers (13–15) indicates an association of sAß with special class of normal blood and CSF lipoproteins, high density lipoproteins (HDL), believed to be a protective factor in atherosclerotic vascular disease. Furthermore, sAß is secreted by hepatic cells as a part of lipoprotein complex (16). Association of Alzheimer's amyloid beta with HDL suggests a mechanism for maintaining it in normal soluble, not aggregated state in blood and body fluids of normal individuals (13–15). Moreover, HDL carry LCAT, the key enzyme of cholesterol removal from the body, activity that in the disease is changed (see above).

On the basis of the observations described above, we tested the effect of Aß on cholesterol esterification in normal human plasma and showed that peptide possesses the inhibitory activity (17). This observation led us to the issue of possible other function of Aß in lipid metabolism. How are cellular effects of Aß in cell culture related to multiple lipid syntheses? Treatment of HepG2 hepatoma cells with Aß decreased the syntheses of various radiolabeled lipid species from [14C]-acetate precursor (18). The lipids whose synthesis was most decreased were cholesterol and phospholipids, the primary constituents of biological membranes affected in AD brain (19, 20). The inhibitory effect reached saturation at <10 to 100 ng of the peptide per 1 ml of media; this may well reflect physiological modulation of lipid metabolism by Aß protein and represent one of the lipid-related functions of sAß as an apolipoprotein constituent of HDL. On the other hand, the higher concentrations of Aß (>100 ng/ml) used in the study are not likely to be reached under physiological condition, but may well represent local AD brain tissue environment. If the inhibitory effects of Aß, reported in the HepG2 cells, similarly take place in the brain tissue, it might explain the reported changes in lipid composition in specific brain regions in AD (5). In addition, the differences in the effects of Aß on the metabolism of unesterified cholesterol (40% maximum inhibition) and phospholipid (25% inhibition) would clarify the cholesterol/phospholipid mole ratio decrease in the AD brain versus age-matched controls, observed previously (21).

The experimental evidence described above suggests that continuous reshaping in lipid physiology occurring with age is closely linked to AD, and that this linkage is part of Alzheimer's pathophysiology rather than a consequence. Notable, lipid and Aß metabolism change may explain some important disease features, like apoE allele variant {epsilon}4/{epsilon}4 significance as a genetic risk factor for late-onset AD (22). Thus, induction of Aß immunoreactivity in the brains of rabbits with enriched dietary cholesterol (23) suggests, assuming the concentration dependent inhibitory effect of Aß protein onto lipid biosynthesis (18), that an increase of Aß concentration within the affected brain tissue might be secondary, and due to previous changes in lipid, particularly cholesterol, metabolism. Such induction of Aß deposition (23) may be also the case in subjects, carrying the {epsilon}4/{epsilon}4 allele of apoE, shown to have elevated plasma cholesterol levels (24, 25). Still, the question of what is the primary event for this purported cascade remains obscure and many other questions remain, which is why we are working hard to bring us closer to solving this part of lipid gerontology and the Alzheimer's mystery in order to alleviate human suffering.

ACKNOWLEDGMENTS

This research was supported by National Institutes of Health grants AG10953 and AG08051, Senetek PLC., Russian Academy of Medical Sciences, Israeli Science Foundation, and Feinberg Fellowship. Part of this research was presented as an essay for the Pharmacia and Science Prize for Young Scientists by Natalia Koudinova, named a finalist in the 1997 competition (26). We thank Drs. H. Kayden, B. Frangione, J. Ghiso, G. Gallo, A. Kumar, B. Raaka, H. Samuels, V. Nussenzweig, M. Segal, E. Yavin, and F. Hitchcock and E. Curley for encouragement and continuous support.

FOOTNOTES

1 Correspondence: Weizmann Institute of Science, Department of Neurobiology/Jaglom, Rehovot 76100, Israel. E-mail: koudin{at}imb.imb.ac.ru

2 Abbreviations: LCAT, lecithin cholesterol acyl transferase; AD, Alzheimer's disease; DS, Down's syndrome; CSF, cerebrospinal fluid; HDL, high density lipoproteins; Aß, amyloid beta protein; sAß, soluble amyloid beta protein.

REFERENCES

  1. Baggio, G., Donazzan, S., Monti, D., Mari, D., Martini, S. Gabelli, C., Dalla Vestra, M., Previato, L., Guido, M., Pigozzo, S., Cortella, I., Crepaldi, G., and Franceschi, C. (1998) Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factor. FASEB J. 12, 433–437[Abstract/Free Full Text]
  2. Knebl, J., DeFazio, P., Clearfield, M., Little, L., McConathy, W., Pherson, R., and Lacko, A. (1994) Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech. Aging. Dev. 73, 69–77
  3. Lacko, A., Hayes, J., McConathy, W., Lacko, I., and Redheendran, R. (1983) Lecithin: cholesterol acyltransferase in Down's syndrome. Clin. Chim. Acta 132, 133–141[Medline]
  4. Murdoch, J.C., Rodger, C.J., Rao, S.S., Fletcher, C.D., and Dunnigan, M.G. (1977) Down's syndrome: an atheroma free model? Br. Med. J. 2, 226–228
  5. Ginsberg, L., Atack, J., Rapoport, S., and Gershfeld, N. (1993) Regional specificity of membrane instability in Alzheimer's disease brain. Brain Res. 615, 355–357[Medline]
  6. Selkoe, D. (1994) Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53, 438–447[Medline]
  7. Sparks, D.L., Hunsaker, J.C. 3d, Scheff, S.W., Kryscio, R.J., Henson, J.L., and Markesbery, W.R. (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging. 11, 601–607[Medline]
  8. Shoji, M., Golde, T., Ghiso, J., Cheung, T., Estus, S., Shaffer, L., Cai, X.-D., McKay, D., Tintner, R., Frangione, B., and Younkin, S. (1992) Production of the Alzheimer Amyloid ß Protein by Normal Proteolytic Processing. Science 258, 126–129[Abstract/Free Full Text]
  9. Haass, C., Schlossmacher, M., Hung, A., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B., Lieberburg, I., Koo, E., Schenk, D., Teplow, D., and Selkoe, D. (1992) Amyloid ß-peptide is produced by cultured cells during normal metabolism. Nature (London) 359, 322–325[Medline]
  10. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992) Isolation and quantification of soluble Alzheimer's ß–peptide from biological fluids. Nature (London) 359, 325–327[Medline]
  11. Strittmatter, W., Saunders, A., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G., and Roses, A. (1993) Apolipoprotein E: high-avidity binding to ß-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981[Abstract/Free Full Text]
  12. Ghiso, J., Matsubara, E., Koudinov, A., Choi-Miura, N., Tomita, M., Wisniewski T., Frangione B. (1993) The cerebrospinal fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40, 40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293, 27–30
  13. Koudinov, A., Matsubara, E., Frangione, B., and Ghiso, J. (1994) The soluble form of Alzheimer's amyloid beta protein is complexed to High Density Lipoprotein 3 and Very High Density Lipoprotein in normal human plasma. Biochem. Biophys. Res. Commun. 205, 1164–1171[Medline]
  14. Koudinov, A., Koudinova, N., Kumar, A., Beavis, R. and Ghiso, J. (1996) Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223, 592–597[Medline]
  15. Koudinov, A., Berezov, T., Kumar, A., and Koudinova, N. (1998) Alzheimer's amyloid ß interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta 270, 75–84[Medline]
  16. Koudinov, A., and Koudinova, N. (1997) Soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol. Internat. 25, 265–271
  17. Koudinov, A., Koudinova, N., and Berezov, T. (1996) Alzheimer's peptides Aß1–40 and Aß1–28 inhibit the plasma cholesterol esterification rate. Biochem. Mol. Biol. Internat. 38, 747–752[Medline]
  18. Koudinova, N., Berezov,T., and Koudinov, A. (1996) Multiple inhibitory effects of Alzheimer's peptide Aß1–40 on lipid biosynthesis in HepG2 cells. FEBS Letters 395, 204–206[Medline]
  19. Ginsberg, L., Atack, J., Rapoport, S. and Gershfeld, N. (1993) Evidence for a membrane lipid defect in Alzheimer disease. Mol. Chem. Neuropathol. 19, 37–46[Medline]
  20. Pettegrew, J., Klunk, W., McClure, R., Panchalingam, K., and Strychor, S. (1988) Phosphomonoesters, phospholipids, and high-energy phosphates in Alzheimer's disease: alterations and physiological significance. In Alzheimer's Disease. New Treatment Strategies (Khachuturian, Z., and Blass; J., eds) pp. 200–205, Marcel Dekker, Inc., New York, USA
  21. Mason, R.P., Shoemaker, W.J., Shajenko, L., Chambers, T.E. and Herbette, L.G. (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413–419[Medline]
  22. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., and Small, G.W. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 261, 921–923[Abstract/Free Full Text]
  23. Sparks, D.L., Scheff, S., Hunsaker, J., Liu, H., Landers, T., and Gross D. (1994) Induction of Alzheimer-like ß-Amyloid Immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94[Medline]
  24. Czech, C., Forstl, H., Hentschel, F., Monning, U., Besthorn, C., Geiger-Kabisch, C., Sattel, H., Masters, C. and Beyreuther, K. (1994) Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. Europ. Arch. Psych. Clin. Neurosci. 243, 291–292
  25. Jarvik, G., Wijsman, E., Kukull, W., Schellenberg, G., Yu, C. and Larson, E. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092–1096[Abstract]
  26. Pharmacia Biotech & Science Prize (1997) Science, 278, 1731[Free Full Text]



This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J-C Lambert, D Mann, F Richard, J Tian, J Shi, U Thaker, S Merrot, J Harris, B Frigard, T Iwatsubo, et al.
Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?
J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 928 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
G. ALIEV, D. SEYIDOVA, M. L. NEAL, J. SHI, B. T. LAMB, S. L. SIEDLAK, H. V. VINTERS, E. HEAD, G. PERRY, J. C. LAMANNA, et al.
Atherosclerotic Lesions and Mitochondria DNA Deletions in Brain Microvessels as a Central Target for the Development of Human AD and AD-Like Pathology in Aged Transgenic Mice
Ann. N.Y. Acad. Sci., November 1, 2002; 977(1): 45 - 64.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. R. Koudinov, T. T. Berezov, and N. V. Koudinova
Cholesterol and Alzheimer's disease: Is there a link?
Neurology, April 9, 2002; 58(7): 1135 - 1135.
[Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koudinov, A. R.
Right arrow Articles by Koudinova, N. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koudinov, A. R.
Right arrow Articles by Koudinova, N. V.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS